

**IN THE SPECIFICATION:**

Please enter the substitute specification submitted herewith in accordance with 37 CFR §1.125(b). Applicant asserts that the substitute specification includes no new matter. The specification has been amended to reflect capitalization of trademarks, and a more descriptive title, as well as to correct any minor typographical errors as requested by the examiner. In addition to the clean copy, a marked-up copy of the substitute specification, indicating the matter added and deleted, is attached hereto.

**IN THE CLAIMS:**

Please amend the claims as follows:

B1  
1. (Amended) A method for enhancing cytotoxicity elicited by a therapeutic antibody in a subject, which method comprises disrupting activation of SHIP by Fc-gamma-receptor IIB (FcγRIIB).

2. (Amended) The method according to claim 1, wherein activation of SHIP by FcγRIIB results from antibody binding to FcγRIIB.

B2  
4. (Amended) The method according to claim 2, wherein antibody binding is inhibited by modifying the Fc region of the antibody to reduce its affinity for FcγRIIB.

**REMARKS**

Claims 1-21 remain pending in this application. Claims 3, 5-9, and 16-21 have been withdrawn from consideration. Claims 1, 2, 4 and 10-15 are under consideration. Applicant notes with appreciation the examiner's extension of the search to include the subject matter of claim 13.

Claims 1, 2, and 4 have been amended herein to more clearly define the present invention. Support for the amendments can be found in the specification. No